Spontaneous Activity of CB2 Receptors Attenuates Stress-Induced Behavioral and Neuroplastic Deficits in Male Mice
Authors:
Open Access
- 21 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 805758
Abstract
The monoaminergic theory of depression/anxiety disorders cannot fully explain the behavioral and neuroplastic changes observed after ADs chronic treatment. Endocannabinoid system, which comprises CB2 receptors, has been associated with the chronic effects of these drugs, especially in stressed mice. CB2-KO mice display more vulnerability to stressful stimuli. In the present study, we hypothesized that the behavioral and neuroplastic effects observed after repeated treatment with the AD escitalopram (Esc) in chronically stressed mice depend on CB2 receptor signaling. Male mice submitted to chronic unpredictable stress (CUS) paradigm (21 days) were treated daily with AM630 (0.01; 0.03 or 0.3 mg/kg, i.p) a CB2 receptor antagonist/inverse agonist. At e 19th day of the CUS protocol, mice were submitted to Open field test and Tail-suspension test to evaluate antidepressant-like behavior. At the end of the stress protocol, mice were submitted to Novel Suppressed Feeding test (day 22nd) to evaluate anxiety-like behavior. In a second series of experiments, male mice treated with Esc (10 mg/kg, daily, 21 days) in the presence or not of AM630 (0.30 mg/kg) were submitted to the same round of behavioral tests in the same conditions as performed in the dose-response curve protocol. Animals were then euthanized under deep anesthesia, and their brains/hippocampi removed for immunohistochemistry (Doublecortin-DCX) or Western Blot assay. Our results demonstrated that chronic treatment with AM630, a CB2 antagonist/inverse agonist, induces anxiolytic-like effects in stressed mice. Moreover, chronic reduction of CB2 receptor endogenous activity by AM630 attenuated the neuroplastic (potentiating stress-induced decreased expression of pro-BDNF, but enhanced pmTOR and DAGL expression in the hippocampus reduced in stressed mice), the antidepressant- but not the anxiolytic-like effects of Esc. AM630 alone or in combination with Esc decreased the expression of DCX + cell in both the subgranular and granular layers of the dentate gyrus (DG), indicating a general reduction of DCX + neuroblasts and a decrease in their migration through the DG layers. We suggest that the antidepressant-like behavior and the pro-neurogenic effect, but not the anxiolytic like behavior, promoted by Esc in stressed mice are, at least in part, mediated by CB2 receptors.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/05551-0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico ((400033/2016-0).)
This publication has 65 references indexed in Scilit:
- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid systemInternational Journal of Neuropsychopharmacology, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse modelEuropean Journal of Neuroscience, 2012
- CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 SignalingJournal of Biological Chemistry, 2012
- Chronic blockade of cannabinoid CB2receptors induces anxiolytic‐like actions associated with alterations in GABAAreceptorsBritish Journal of Pharmacology, 2011
- Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in MiceNeuropsychopharmacology, 2011
- Endogenous cannabinoid signaling is essential for stress adaptationProceedings of the National Academy of Sciences, 2010
- Depression‐resistant endophenotype in mice overexpressing cannabinoid CB 2 receptorsBritish Journal of Pharmacology, 2010
- Cannabinoid CB2 receptors in human brain inflammationBritish Journal of Pharmacology, 2008
- Neuropsychobiological Evidence for the Functional Presence and Expression of Cannabinoid CB2 Receptors in the BrainNeuropsychobiology, 2006